Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jackson, L. A.
Right arrow Articles by Grayston, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackson, L. A.
Right arrow Articles by Grayston, J. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 411-414
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease

Lisa A. Jacksona,*, Douglas K. Stewartb, San-Pin Wangc , Dennis B. Cooked, Truman Cantrelld and J. Thomas Graystona

a Department of Epidemiology, University of Washington, Seattle b Department of Medicine, University of Washington, Seattle c Department of Pathobiology, University of Washington, Seattle d The Heart Institute, Spokane, Washington, USA

A pilot study of azithromycin treatment following percutaneous coronary revascularization procedures was performed to assess safety and the effect of azithromycin treatment on anti-Chlamydia pneumoniae antibody titres. Patients were randomized to a 1 month course of azithromycin (total dose of 8.0 g) or placebo. Safety and compliance were assessed at 2 and 4 weeks and serological testing was performed on samples obtained at enrolment and at 6 months post-enrolment. Azithromycin was well tolerated at this dose. No effect of treatment on antibody titres was demonstrated. These results support further clinical trials to assess the effect of azithromycin treatment on cardiovascular disease outcomes.

* Correspondence address. Box 356236, University of Washington, Seattle, WA 98195-7236, USA. Tel: +1-206-616-7439; Fax: +1-206-543-8525; E-mail: lajack{at}u.washington.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
H. F. Berg, B. Maraha, A. van der Zee, S. K. Gielis, P. J. M. Roholl, G.-J. Scheffer, M. F. Peeters, and J. A. J. W. Kluytmans
Effect of Clarithromycin Treatment on Chlamydia pneumoniae in Vascular Tissue of Patients with Coronary Artery Disease: a Randomized, Double-Blind, Placebo-Controlled Trial
J. Clin. Microbiol., March 1, 2005; 43(3): 1325 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. P. Higgins
Chlamydia pneumoniae and Coronary Artery Disease: The Antibiotic Trials
Mayo Clin. Proc., March 1, 2003; 78(3): 321 - 332.
[Abstract] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. Boman and M. R. Hammerschlag
Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies
Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20.
[Abstract] [Full Text]

Home page
 CirculationHome page
J. Zhu, F. J. Nieto, B. D. Horne, J. L. Anderson, J. B. Muhlestein, and S. E. Epstein
Prospective Study of Pathogen Burden and Risk of Myocardial Infarction or Death
Circulation, January 2, 2001; 103(1): 45 - 51.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.